Generalised myasthenia gravis (gMG)

gMG

Learn more about gMG, a rare, autoimmune antibody-mediated disease that affects the postsynaptic membrane at the neuromuscular junction of skeletal muscles1–3

Diagnosing gMG

Discover the key steps in the diagnosis of gMG

Guidelines & recommendations

Review international consensus guidance & recommendations

Symptoms of gMG

Recognise the common signs and symptoms of gMG

Treatment types

Understand the need for an individualised treatment approach
ULTOMIRIS® is indicated as an add–on to standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody–positive.4
Please consult the Summary of Product Characteristics prior to prescribing.

About ULTOMIRIS®

Learn more

ULTOMIRIS® in the treatment of anti-AChR-positive gMG

MECHANISM of Action

Learn more

Review and explore the mechanism of action of ULTOMIRIS®

Efficacy and safety

Learn more

Explore clinical data looking at the efficacy & safety of ULTOMIRIS®

Dosing calculator

Learn more

Access our easy-to-use tool to calculate your patient's dosing requirements

Dosing and administration

Learn about the weight-based dosing regimen of ULTOMIRIS®

EAN 2024

Missed our symposia from this year’s EAN congress? Catch up by watching the full presentations here

e-publications

Navigate through recent publications on gMG and ULTOMIRIS® to learn more about how to recognise and treat gMG

webinars

Leading experts in gMG present educational updates in our latest webinar series
Sign up now to be informed of our upcoming symposia, our latest educational updates, and to be alerted to our webinars, hosted by world leading experts in gMG.
Keep me up to date

FIRST NAME*

SURNAME*

DISEASE AREA OF INTEREST*

Specialty*

EMAIL*

COUNTRY*
SOLIRIS® is indicated in refractory generalised myasthenia gravis (gMG) in patients aged 6 years and above who are anti-acetylcholine receptor (AChR) antibody-positive.5
Please consult the Summary of Product Characteristics prior to prescribing.

About Soliris®

Learn more

SOLIRIS® in the treatment of anti-AChR-positive gMG

MECHANISM of action

Learn more

Review and explore the mechanism of action of SOLIRIS®

EFFICACY & SAFETY

Learn more

Explore clinical data looking at the efficacy & safety of SOLIRIS®

DOSING & ADMINISTRATION

Learn more

Learn about the phases of SOLIRIS® dosing and administration

 advance I am a healthcare professional registered in the EU I am not a
healthcare professional
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion Pharmaceuticals by contacting: https://contactazmedical.astrazeneca.com/
AChR, anti-acetylcholine receptor; gMG, generalised myasthenia gravis.
Gilhus NE, et al. Myasthenia Gravis. Nat Rev Dis Primers. 2019;5(1):30. Koneczny I, Herbst R. Myasthenia gravis: Pathogenic effects of autoantibodies on neuromuscular architecture. Cells. 2019;8(7):671. Melzer N, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: A supplement to the Guidelines of the German Neurological Society. J Neurol. 2016;263(8)1473–1494. ULTOMIRIS® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf. Last accessed: May 2024. SOLIRIS® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf. Last accessed: May 2024.